Sugi Predict

Sugi Predict / Compounds / SCHEMBL1644909

SCHEMBL1644909

SCHEMBL1644909

CON(C)C(=O)c1ccc2nccnc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.56
▸ HPGD P15428 4/20 0.54
▸ RECQL P46063 1/20 0.54
▸ HTT P42858 2/20 0.50
▸ RAB9A P51151 5/20 0.49
▸ MAPT P10636 4/20 0.49
▸ NPC1 O15118 4/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ TP53 P04637 1/20 0.49
▸ ALDH1A1 P00352 3/20 0.48
▸ CYP3A4 P08684 2/20 0.47
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ GAA P10253 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ MLYCD O95822 1/20 0.44
▸ ATM Q13315 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30134027 0.88 POLB (0.44) POLBHPGDRECQLHTTRAB9A
SCHEMBL28940987 0.83 POLB (0.61) POLBHPGDRECQLHTTRAB9A
SCHEMBL29977012 0.82 HTT (0.50) POLBHPGDRECQLHTTRAB9A
SCHEMBL22116897 0.82 HTT (0.50) POLBHPGDRECQLHTTRAB9A
SCHEMBL361516 0.82 ALOX15 (0.65) POLBHTTRAB9AMAPTNPC1
SCHEMBL30133901 0.81 POLB (0.41) POLBHPGDRECQLHTTRAB9A
SCHEMBL30133934 0.81 POLB (0.41) POLBHPGDRECQLHTTRAB9A
SCHEMBL3603807 0.80 POLB (0.58) POLBHPGDRECQLHTTRAB9A
SCHEMBL14783903 0.80 HPGD (0.42) POLBHPGDRECQLHTTRAB9A
SCHEMBL17025587 0.80 KDM4E (0.39) POLBHPGDRECQLHTTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119119033-A Pyrazolopyridone compounds 百济神州有限公司 2024-12-13 — — CN disclosed
US-20240300951-A1 Pyrazolopyridinone Compounds BEIGENE LTD. (KY) 2024-09-12 — — US disclosed
US-20240270751-A1 Pyrazolopyridinone Compounds BEIGENE LTD. (KY) 2024-08-15 — — US disclosed
EP-4380936-A1 PYRAZOLOPYRIDINONE COMPOUNDS BeiGene, Ltd. (KY) 2024-06-12 — — EP disclosed
CN-117836296-A Pyrazolopyridone compounds 百济神州有限公司 2024-04-05 — — CN disclosed
WO-2023011456-A1 PYRAZOLOPYRIDINONE COMPOUNDS BEIGENE, LTD. (KY) 2023-02-09 — — WO disclosed
CN-115403531-A Chemical entities, compositions, and methods as kinase inhibitors 润新生物公司 2022-11-29 — — CN disclosed
US-20220251049-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2022-08-11 — — US disclosed
US-11358961-B2 Anti-HCMV compositions and methods EVRYS BIO, LLC (US) 2022-06-14 — — US disclosed
CN-108794411-B Certain chemical entities, compositions, and methods 润新生物公司 2022-06-07 — — CN disclosed
EP-1773330-A4 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO INC (US) 2009-01-21 — — EP disclosed
EP-1971594-A2 SUBSTITUTED PYRAZALONES Biogen Idec MA Inc. (US) 2008-09-24 — — EP disclosed
US-20080108620-A1 Substituted Pyrazoles, Compositions Containing such Compounds and Methods of Use MERCK & CO., INC. (US) 2008-05-08 — — US disclosed
EP-1909788-A2 PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES RESVERLOGIX CORP. (CA) 2008-04-16 — — EP disclosed
US-20070179144-A1 for treatment of deficiencies in hematopoietic cells GLAXOSMITHKLINE LLC 2007-08-02 — — US disclosed
US-20070179144-A1 for treatment of deficiencies in hematopoietic cells GLAXOSMITHKLINE LLC 2007-08-02 — — US disclosed
WO-2007059359-A2 SUBSTITUTED PYRAZALONES BIOGEN IDEC MA INC. (US) 2007-05-24 — — WO disclosed
EP-1773330-A2 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE Merck & Co., Inc. (US) 2007-04-18 — — EP disclosed
WO-2007016525-A2 PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES RESVERLOGIX CORP. (CA) 2007-02-08 — — WO disclosed
WO-2006014618-A2 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO., INC. (US) 2006-02-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108620-A1 Substituted Pyrazoles, Compositions Containing such Compounds and Methods of Use GLP1R, GCGR, GPR119 POLB 4154/4885HPGD 713/4885RECQL 3705/4885
US-11358961-B2 Anti-HCMV compositions and methods RPL35, RPL7, RPL5 POLB 44/4885HPGD 3555/4885RECQL 1243/4885
US-20240300951-A1 Pyrazolopyridinone Compounds NFATC1, CD4, PBK POLB 1119/4885HPGD 1034/4885RECQL 2747/4885
US-20220251049-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS BRAF, NRAS, KRAS POLB 1414/4885HPGD 1123/4885RECQL 110/4885
US-20240270751-A1 Pyrazolopyridinone Compounds NFATC1, CD4, PBK POLB 1119/4885HPGD 1034/4885RECQL 2747/4885
US-20070179144-A1 for treatment of deficiencies in hematopoietic cells HCLS1, HIPK3, HYPK POLB 3466/4885HPGD 609/4885RECQL 336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.